CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China
Summary
The Chinese pharmaceutical market is the second largest in the world in terms of value. The increasing elderly population, expanding public insurance and regulatory reforms aimed at innovation and minimizing approval timelines are some of the factors driving the Chinese pharmaceutical market.
China Food and Drug Administration (CFDA) has released several policies to reform the healthcare market. Reforms to clinical trial processes have helped to reduce R&D costs and time, while initiatives for the market authorization process have helped to minimize regulatory delays.
The pharmaceutical industry - comprising the manufacturing of Western Medicines, Active Pharmaceutical Ingredients (API), Traditional Chinese Medicine (TCM), Biologics and Herbal Medicines - was valued at $168.6 billion in 2010 and grew to $424.6 billion in 2016. It is forecast to be $132.9 billion in 2018 and reach $209 billion by 2022.
The Chinese medical device market was valued at $36 billion in 2015, which increased to $40.1 billion in 2017. In order to further boost up the healthcare market, in September 2018, the Chinese government signed about $648 million worth of healthcare and life sciences deals with the UK government. The Chinese government also abolished the 15-year old government led drug pricing system and introduced a reform regarding drug pricing. This reform partially removed government control on drug prices, permitting more control of the market instead.
The latest report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China, is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.
Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in the China, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Merck, Novartis, Jiangsu Hengrui Medicine, Sinopharm and Tong Ren Tang) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Boston Scientific and Shinva)
- Detailed analysis about recent completed deals in the pharmaceutical and medical device market of China
- Porter’s five forces analysis for pharmaceutical and medical devices market of China
- An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
- Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the Chinese healthcare market.
Reasons to buyThis report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving the Chinese healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
- Identify, understand, and capitalize on the opportunities and challenges in the Chinese healthcare market.
- Executive Summary
- Overview of Pharmaceutical Market
- Overview of Medical Device Market
- Deals Analysis
- Porter’s Five Forces Model
- Market Access
- Country Healthcare Landscape
- Opportunities and Challenges
- Appendix
- List of Tables
- Table 1: Biosimilars in Development by Chinese Companies, China, 2016
- Table 2: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016
- Table 3: Ophthalmic Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2015
- Table 4: Orthopedic Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2017
- Table 5: Diagnostic Imaging Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2015
- Table 6: Nephrology and Urology Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2016
- Table 7: Cardiovascular Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2017
- Table 8: Drug Classification System, China, 2017
- Table 9: Medical Device Classification, China, 2016
- Table 10: Trademark Process Timeline, China, 2017
- Table 11: Documents for Advertising Application, China, 2017
- Table 12: Label/Insert Sheet Information, China, 2017
- Table 13: Key Improvement Indicators, Healthy China 2030
- Table 14: Trade Fairs, China, 2018-2019
- List of Figures
- Figure 1: Pharmaceutical Market, China, Revenue ($bn), 2010-2017
- Figure 2: Medical Device Market, China, Revenue ($bn), 2015-2020
- Figure 3: Country Profile, China, 2017
- Figure 4: Pharmaceutical Market, China, Revenue ($bn), 2010-2017
- Figure 5: Pharmaceutical Market, China, Revenue Forecast ($bn), 2018-2022
- Figure 6: Pharmaceutical Exports ($bn), China, 2010-2017
- Figure 7: Top Export Partners, China, 2017
- Figure 8: Pharmaceutical Imports ($bn), China, 2010-2017
- Figure 9: Top Import Partners, China, 2017
- Figure 10: USTR Findings, 2018
- Figure 11: US-China Trade War Timeline, 2018
- Figure 12: Pharmaceutical Drug Sales Channel, China, 2016
- Figure 13: Supply Chain Prior to 2017
- Figure 14: Two Invoice System
- Figure 15: Policies for Biosimilar Promotion, China, 2018
- Figure 16: Major Biosimilar Sales ($m), China, 2016
- Figure 17: Traditional Chinese Medicine Production (10,000 tons), China, 2010-2016
- Figure 18: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016
- Figure 19: Pharmaceutical Market, Major Players, 2017
- Figure 20: Medical Device Market, China, Revenue ($bn), 2015-2020
- Figure 21: Medical Device Market, China, Revenue Forecast ($bn), 2021-2025
- Figure 22: Medical Device Market, China, Revenue by Segment ($bn), 2017
- Figure 23: Ophthalmic Devices Market, China, Revenue ($m), 2015-2022
- Figure 24: Ophthalmic Devices Market, China, Market Share of Major Players (%), 2015
- Figure 25: Orthopedic Devices Market, China, Revenue ($m), 2015-2020
- Figure 26: Orthopedic Devices Market, China, Market Share of Major Companies (%), 2017
- Figure 27: Diagnostic Imaging Devices Market, China, Revenue ($bn), 2015-2020
- Figure 28: Diagnostic Imaging Devices Market, China, Market Share of Major Players (%), 2015
- Figure 29: Nephrology and Urology Devices Market, China, Revenue ($m), 2015-2022
- Figure 30: Nephrology and Urology Devices Market, China, Market Share of Major Players (%), 2016
- Figure 31: Cardiovascular Devices Market, China, Revenue ($bn), 2015-2022
- Figure 32: Cardiovascular Devices Market, China, Market Share of Major Players (%), 2017
- Figure 33: Diagnostic Market, China, Revenue ($bn), 2015-2020
- Figure 34: Diagnostic Market, China, Revenue ($bn), 2021-2025
- Figure 35: Medical Device Market, China, Revenue ($bn) of Major Companies, 2017
- Figure 36: Deal Value and Deal Count, Pharmaceutical Market, China, 2017-2018
- Figure 37: Deal Value and Deal Count Quarterly, Pharmaceutical Market, China, 2017-2018
- Figure 38: Deal Value and Deal Count Sub-types, Pharmaceutical Market, China, 2017-2018
- Figure 39: Top Five Therapy Areas by Deal Value, Pharmaceutical Market, China, 2017-2018
- Figure 40: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, China, 2017-2018
- Figure 41: M&A Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count)
- Figure 42: Venture Financing Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count)
- Figure 43: Private Equity Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count)
- Figure 44: Medical Device Market Deals (by deal value, $bn), China, 2017-2018
- Figure 45: Medical Device Market Deals (by deal count), China, 2017-2018
- Figure 46: Medical Device Market Deals Share (by deal count), China, 2017-2018
- Figure 47:Medical Device Market Deals Share (by deal value), China, 2017-2018
- Figure 48: Medical Device, China, Top Therapy Area by Deal Value, 2017-2018
- Figure 49: Medical Devices, China, M&A Deals by Therapy Area, 2017-2018
- Figure 50: Medical Devices, China, Venture Financing Deals by Therapy Area, 2017-2018
- Figure 51: Medical Devices, China, Top Therapy Area by Deal Number, 2017-2018
- Figure 52: Medical Devices, China, Private Equity Deals by Therapy Area, 2017-2018
- Figure 53: Healthcare System, China, 2017
- Figure 54: National Reimbursement Drug List Process, China, 2017
- Figure 55: National Reimbursement Drug List Classification, China, 2017
- Figure 56: Public Insurance Schemes, China, 2017
- Figure 57: Out-of-Pocket Expenditure (% of total expenditure on health), China, 2010-2017
- Figure 58: Annual Rate of Change (%), Health Care Price Index, China, 2010-2016
- Figure 59: Pricing Policies, China, 2017
- Figure 60: Drug Movement from Market Authorization to Patient Use, China, 2016
- Figure 61: Ministry of Food and Drug Safety, Organization Chart, 2017
- Figure 62: Timeline of CFDA Reforms, China, 2015-2018
- Figure 63: Center for Drug Evaluation Organization Chart, China, 2017
- Figure 64: Drug Approval Process, China, 2017
- Figure 65: Generic Drug Approval Process, China, 2017
- Figure 66: Medical Device Approval Process, China, 2017
- Figure 67: Patent Approval Process, China, 2016
- Figure 68: Proposed Patent Linkage System, China, 2017
- Figure 69: Trademark Process, China, 2017
- Figure 70: Advertising Application Approval Process, China, 2017
- Figure 71: Key Announcements and Updates, Healthy China 2020, 2009-2016
- Figure 72: Healthy China 2030, Strategic Goals
- Figure 73: Hospitals (Number), China, 2010-2017
- Figure 74: Hospitals by Type (Number), China, 2010-2017
- Figure 75: Diagnostic Equipment (installed base), China, 2015-2012
- Figure 76: Hospital Beds (per 1,000 population), China, 2010-2017
- Figure 77: Medical Institution Beds (Urban)(per 1,000 population), China, 2010-2017
- Figure 78: Medical Institution Beds (Rural)(per 1,000 population), China, 2010-2017
- Figure 79: Life Expectancy (in years), China, 2010-2017
- Figure 80: Immunization Rate (%), China, 2010-2017
- Figure 81: PM2.5 (μg per m3), China, 2010-2017
- Figure 82: CO2 Emissions (metric tons per capita), China, 2010-2017
- Figure 83: Physicians (per 1,000 population), China, 2010-2017
- Figure 84: Nurses (per 1,000 population), China, 2010-2017
- Figure 85: Dentists, (per 1,000 population), China, 2010-2017
- Figure 86: Pharmacists, (per 1,000 population), China, 2010-2017
- Figure 87: Major Causes of Mortality (Death rate (%)), China, 2016
- Figure 88: Major Causes of Male Mortality (Death rate (%)), China, 2016
- Figure 89: Major Causes of Female Mortality (Death rate (%)), China, 2016
- Figure 90: Disability-Adjusted Life Years by Major Disease (‘000), China, 2015
- Figure 91: Healthcare Expenditure as Percentage of GDP (%), China, 2010-2017
- Figure 92: Public-Private Share (%), China, 2010-2017
- Figure 93: Opportunities & Challenges, China